Want to see TSE:PREV full AI Analyst Report?
Top Page
PreveCeutical Medical
(PREV)
Select Model
Select Model
Rating:43Neutral
Price Target:
C$0.02
▼(-5.00% Downside)
Action:Upgraded
Date:08/06/26
The score is primarily driven down by very weak financial performance—no revenue base, worsening losses/cash burn in 2025, and a stressed balance sheet with negative equity and rising debt. Technical signals are neutral-to-weak (negative MACD and price below the 200-day average), and valuation support is limited due to negative earnings and no dividend yield.
Positive Factors
Platform & R&D Focus
PreveCeutical's focus on developing active pharmaceutical ingredients and multiple therapeutic programs creates a durable R&D platform. Owning APIs and early-stage assets enables future licensing, partnerships, or asset sales, providing multiple non-revenue value realization paths over months.
Negative Factors
No Commercial Revenue
The absence of any commercial revenue across multiple years means the company lacks product-market validation and must fund operations via external capital or partnerships. This structural lack of recurring sales raises execution and financing risk over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform & R&D Focus
PreveCeutical's focus on developing active pharmaceutical ingredients and multiple therapeutic programs creates a durable R&D platform. Owning APIs and early-stage assets enables future licensing, partnerships, or asset sales, providing multiple non-revenue value realization paths over months.
Read all positive factors
PreveCeutical Medical (PREV) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$8.97M
Dividend YieldN/A
Average Volume (3M)143.42K
Price to Earnings (P/E)―
Beta (1Y)-0.47
Revenue GrowthN/A
EPS Growth-36.36%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding598,186,950
10 Day Avg. Volume276,937
30 Day Avg. Volume143,419
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PreveCeutical Medical Business Overview & Revenue Model
Company Description
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid...
How the Company Makes Money
null...
PreveCeutical Medical Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -14.43K | -10.10K | -9.86K | -9.89K | -5.09K |
| EBITDA | -1.35M | -837.46K | -955.09K | -1.23M | -829.83K |
| Net Income | -1.58M | -1.17K | -1.27M | -1.48M | -1.73M |
Balance Sheet | |||||
| Total Assets | 1.45M | 225.66K | 181.51K | 189.14K | 161.20K |
| Cash, Cash Equivalents and Short-Term Investments | 10.24K | 59.14K | 1.43K | 5.62K | 16.06K |
| Total Debt | 4.68M | 4.46M | 3.89M | 3.23M | 2.93M |
| Total Liabilities | 7.69M | 6.86M | 5.96M | 4.82M | 4.27M |
| Stockholders Equity | -6.24M | -6.64M | -5.78M | -4.64M | -4.10M |
Cash Flow | |||||
| Free Cash Flow | -1.72M | -428.49K | -296.97K | -222.64K | -481.59K |
| Operating Cash Flow | -1.72M | -426.69K | -296.97K | -222.64K | -426.39K |
| Investing Cash Flow | -2.96K | -1.80K | 0.00 | 850.00 | -52.70K |
| Financing Cash Flow | 1.68M | 487.64K | 293.62K | 211.72K | 136.75K |
PreveCeutical Medical Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
<0.01
Negative
44.45
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PREV, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 44.45 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PREV.
PreveCeutical Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$18.02M | -11.41 | -67.05% | ― | 224.46% | 28.37% | |
44 Neutral | C$46.14M | -25.20 | 19.88% | ― | ― | 15.07% | |
43 Neutral | C$8.97M | -5.00 | 23.09% | ― | ― | -36.36% | |
39 Underperform | C$13.64M | -4.41 | 54.18% | ― | 4.30% | 38.28% |
* Healthcare Sector Average
TSE:PREV
PreveCeutical Medical
0.02
-0.02
-57.14%
TSE:DOSE
Rapid Dose Therapeutics Corp
0.11
-0.07
-38.89%
TSE:BETR
BetterLife Pharma
0.32
0.23
270.59%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.21
0.08
64.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.